open access

Vol 2, No 1 (2009)
ORIGINAL PAPERS
Published online: 2009-02-12
Get Citation

HBsAg detection in blood donors in Poland, 1995–2004

Piotr Grabarczyk, Halina Seyfried, Ewa Brojer, Magdalena Rosińska, Maria Mikulska, Magdalena Łętowska, the Polish Blood Transfusion Service Vir Group
Journal of Transfusion Medicine 2009;2(1):20-25.

open access

Vol 2, No 1 (2009)
ORIGINAL PAPERS
Published online: 2009-02-12

Abstract

Background: At the end of the 1980s the incidence rate of hepatitis B in Poland was one of the highest in Europe. The aim of our study was to analyse HBsAg detection rates in Polish blood donors in the years 1995–2004.
Materials and methods: Between 1 January 1995 and 31 December 2004, 4.669.435 donors were screened for HBsAg: 1.896.770 first time donors and 2,772,665 repeat donors.
Results: HBs antigen was detected in 0.35% of all Polish blood donors; in 0.79% of the first time donors and 0.06% of the repeat donors. The HBsAg detection rate decreased during the analysed period, from about 1% in 1995 to 0.67% in 2004 for first time donors, and from 0.088% to 0.017% in repeat blood donors. The relative decline rate was greater for repeat donors than for first time donors (20.7% per year and 5.4 % per year, respectively). A wide range of trends for HBsAg prevalence was observed in different regions of the country. For repeat donors it ranged from a 33.5% decrease per year in the southwest to a stable level (about 0%) in the northeast. In most regions, a decreasing tendency was observed for first time donors (max 10.9% per year) although a 3.4% per year increase was observed in the central region (łódzkie).
Conclusions: In 1995–2004 the frequency of HBV infection marker in Poland was higher than in most European countries. A decreasing tendency for HBsAg detection in blood donors was observed. Such a trend was found both in repeat and first time donors. In one region, however, an inverse tendency was observed.

Abstract

Background: At the end of the 1980s the incidence rate of hepatitis B in Poland was one of the highest in Europe. The aim of our study was to analyse HBsAg detection rates in Polish blood donors in the years 1995–2004.
Materials and methods: Between 1 January 1995 and 31 December 2004, 4.669.435 donors were screened for HBsAg: 1.896.770 first time donors and 2,772,665 repeat donors.
Results: HBs antigen was detected in 0.35% of all Polish blood donors; in 0.79% of the first time donors and 0.06% of the repeat donors. The HBsAg detection rate decreased during the analysed period, from about 1% in 1995 to 0.67% in 2004 for first time donors, and from 0.088% to 0.017% in repeat blood donors. The relative decline rate was greater for repeat donors than for first time donors (20.7% per year and 5.4 % per year, respectively). A wide range of trends for HBsAg prevalence was observed in different regions of the country. For repeat donors it ranged from a 33.5% decrease per year in the southwest to a stable level (about 0%) in the northeast. In most regions, a decreasing tendency was observed for first time donors (max 10.9% per year) although a 3.4% per year increase was observed in the central region (łódzkie).
Conclusions: In 1995–2004 the frequency of HBV infection marker in Poland was higher than in most European countries. A decreasing tendency for HBsAg detection in blood donors was observed. Such a trend was found both in repeat and first time donors. In one region, however, an inverse tendency was observed.
Get Citation

Keywords

HBV; HBsAg; blood donors; screening

About this article
Title

HBsAg detection in blood donors in Poland, 1995–2004

Journal

Journal of Transfusion Medicine

Issue

Vol 2, No 1 (2009)

Pages

20-25

Published online

2009-02-12

Bibliographic record

Journal of Transfusion Medicine 2009;2(1):20-25.

Keywords

HBV
HBsAg
blood donors
screening

Authors

Piotr Grabarczyk
Halina Seyfried
Ewa Brojer
Magdalena Rosińska
Maria Mikulska
Magdalena Łętowska
the Polish Blood Transfusion Service Vir Group

References (19)
  1. Magdzik WW. Hepatitis B epidemiology in Poland, Central and Eastern Europe and the newly independent states. Vaccine. 2000; 18 Suppl 1: S13–S16.
  2. Magdzik W, Czarkowski MP. [Epidemiological situation of hepatitis B in Poland in the years 1979-2004]. Przegl Epidemiol. 2006; 60(3): 471–480.
  3. 1996 www who int. www.who.int//vaccines-documents/ (1996).
  4. Muller-Breitkreutz K, Evers T, Perry R. Viral marker rates among unpaid blood donors in Europe decreased from 1990 to 1996. Euro Surveill. 1998; 3(7): 71–76.
  5. Pillonel J, Saura C, Courouce AM. Screening of viral markers for HIV HBV and HCV infections in blood donors in France and residual risk of viral transmission by blood transfusion. Euro Surveill. 1998; 3(7): 76–79.
  6. Zou S, Notari EP, Stramer SL, et al. ARCNET Research Group. Patterns of age- and sex-specific prevalence of major blood-borne infections in United States blood donors, 1995 to 2002: American Red Cross blood donor study. Transfusion. 2004; 44(11): 1640–1647.
  7. Giusti G, Gaeta GB, Russo M, et al. HBsAg carriers among blood donors in Italy--a multicentre study in 107 blood banks. Infection. 1989; 17(4): 237–239.
  8. Tanaka J, Kumagai J, Katayama K, et al. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology. 2004; 47(1): 32–40.
  9. Sarkodie F, Adarkwa M, Adu-Sarkodie Y, et al. Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sang. 2001; 80(3): 142–147.
  10. Gawęda J, Kłos M, Kruszewski J. Ocena stanu epidemiologicznego zakażeń HBV, HIV i CMV wśród honorowych dawców krwi — żołnierzy służby zasadniczej. Lek. Wojsk. 1999; 75 (9-12): 494–496.
  11. Kuśmierczyk J, Zatorska J, Ras J, et al. The prevalence of antiHBc antibodies in blood donors in southern Poland. Vox Sang. 2006(supl. 3): 56.
  12. Magdzik W, Czarkowski MP. [Coverage of vaccination against hepatitis B in Poland in 2004]. Przegl Epidemiol. 2006; 60(2): 185–192.
  13. Van der Bij AK, Coutinho RA, Van der Poel CL. Surveillance of risk profiles among new and repeat blood donors with transfusion-transmissible infections from 1995 through 2003 in the Netherlands. Transfusion. 2006; 46(10): 1729–1736.
  14. Technical briefing document Copenhagen, 12 September 2006, Trends in sexually transmitted infections and HIV in the European Region, 1980–2005. www.euro.who.int.document//RC56/etbab.pdf.
  15. Hsu HY, Chang MH, Ni YH, et al. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut. 2004; 53(10): 1499–1503.
  16. Brojer E, Grabarczyk P, Liszewski G, et al. and the Polish Blood Transfusion Service Viral Study Group: Characterization of HBV DNA positive/HBsAg negative blood donors identified in the Polish NAT screening program. Hepatology. 2006; 44: 6.
  17. González R, Echevarria JM, Avellón A, et al. Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain. Transfusion. 2006; 46(7): 1138–1142.
  18. Roth WK, Weber M, Petersen D, et al. NAT for HBV and anti-HBc testing increase blood safety. Transfusion. 2002; 42(7): 869–875.
  19. Murokawa H, Yoshikawa A, Ohnuma H, et al. Japanese Red Cross NAT Screening Research Group. Epidemiology of blood donors in Japan, positive for hepatitis B virus and hepatitis C virus by nucleic acid amplification testing. Vox Sang. 2005; 88(1): 10–16.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl